Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | MMP1 | P03956 | 1/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | MMP8 | P22894 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | SNCA | P37840 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2277355 | 1.00 | CA1 (0.58) | CA1CA2MMP1MMP2MMP9 | |
| Nitrogen SCHEMBL6228389 | 0.95 | CA1 (0.54) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL29991938 | 0.95 | GAA (0.62) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL34 | 0.95 | GAA (0.62) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL1705904 | 0.95 | GAA (0.62) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL5068661 | 0.95 | GAA (0.62) | CA1CA2MMP1MMP2MMP9 | |
| P-Xylene SCHEMBL8660591 | 0.95 | GAA (0.62) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL31313 | 0.95 | GAA (0.62) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL11432043 | 0.95 | GAA (0.62) | CA1CA2MMP1MMP2MMP9 | |
| Dimethylamine SCHEMBL1157465 | 0.93 | SMN1; SMN2 (0.58) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109313988-B | Graphene frame for supercapacitor | 加利福尼亚大学董事会 | 2023-09-05 | — | — | CN | claimed |
| US-20230241041-A1 | LURBINECTEDIN IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | PHARMA MAR, S.A. (ES) | 2023-08-03 | — | — | US | claimed |
| US-11348740-B2 | Graphene frameworks for supercapacitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-31 | — | — | US | claimed |
| US-20210061773-A1 | COMPOUND AND USE THEREOF IN MEDICINE | CHANGSHA HOOZ BIOSCIENCE AND TECHNOLOGY CO., LTD (CN) | 2021-03-04 | — | — | US | claimed |
| US-20200294729-A1 | GRAPHENE FRAMEWORKS FOR SUPERCAPACITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-17 | — | — | US | claimed |
| EP-3408858-A1 | GRAPHENE FRAMEWORKS FOR SUPERCAPACITORS | The Regents of the University of California (US) | 2018-12-05 | — | — | EP | claimed |
| US-20170213656-A1 | GRAPHENE FRAMEWORKS FOR SUPERCAPACITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-07-27 | — | — | US | claimed |
| US-20170022210-A1 | PROCESS FOR IMPROVED OXYCODONE SYNTHESIS | RHODES TECHNOLOGIES (US) | 2017-01-26 | — | — | US | claimed |
| CN-103717570-B | The preparation of sitagliptin intermediate | LEK PHARMACEUTICALS D.D. (SI) | 2016-05-18 | — | — | CN | claimed |
| WO-2015091827-A1 | BENDAMUSTINE DERIVATIVES AND RELATED COMPOUNDS | SCHICKANEDER HELMUT (DE) | 2015-06-25 | — | — | WO | claimed |
| EP-1663150-A2 | NOVEL INHALATION POWDER COMPRISING THE CGRP ANTAGONIST 1-[ N2-[3,5-DIBROMO-N-[[4-(3,4-DIHYDRO-2(1H)-OXOQUINAZOLIN-3-YL)-1-PIPERIDINYL]CARBONYL]-D-TYROSYL]-L-LYSYL]-4-(4-PYRIDINYL)-PIPERAZINE | Boehringer Ingelheim International GmbH (DE) | 2006-06-07 | — | — | EP | claimed |
| EP-1658051-A1 | MICROPARTICLES COMPRISING THE CGRP ANTAGONIST 1-¬N2 -¬ 3,5-DIBROMO- N-¬¬4-(3,4-DIHYDRO-2(1H)-OXOQUINAZOLIN-3-YL)-1-PIPERIDINYL|CARBONYL|-D-TYROSYL|-L-LYSYL|-4-(4-PYRIDINYL)-PIPERAZINE METHOD FOR PRODUCTION AND USE THEREOF AS INHALATION POWDER | Boehringer Ingelheim International GmbH (DE) | 2006-05-24 | — | — | EP | claimed |
| CN-1633305-A | Pharmaceutical compositions based on anticholinergics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-06-29 | — | — | CN | claimed |
| WO-2005018604-A2 | NOVEL INHALATION POWDER COMPRISING THE CGRP ANTAGONIST 1-[N2-[3,5-DIBROMO-N-[[4-(3,4-DIHYDRO-2(1H)-OXOQUINAZOLIN-3-YL)-1-PIPERIDINYL]CARBONYL]-D-TYROSYL]-L-LYSYL]-4-(4-PYRIDINYL)-PIPERAZINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-03 | — | — | WO | claimed |
| WO-2005018603-A2 | SPRAY-DRIED AMORPHOUS BIBN 4096 METHOD FOR PRODUCTION AND USE THEREOF AS INHALANT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-03 | — | — | WO | claimed |
| WO-2005018609-A1 | MICROPARTICLES COMPRISING THE CGRP ANTAGONIST 1-[N2-[3,5-DIBROMO-N-[[4-(3,4-DIHYDRO-2(1H)-OXOQUINAZOLIN-3-YL)-1-PIPERIDINYL]CARBONYL]-D-TYROSYL]-L-LYSYL]-4-(4-PYRIDINYL)-PIPERAZINE METHOD FOR PRODUCTION AND USE THEREOF AS INHALATION POWDER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-03 | — | — | WO | claimed |
| EP-0056692-B1 | 7-SUBSTITUTED CAMPTOTHECIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1985-08-14 | — | — | EP | claimed |
| EP-0073626-A2 | Manufacture of acyl isethionates | UNILEVER PLC (GB) | 1983-03-09 | — | — | EP | claimed |
| EP-0007097-B1 | TENSIO-ACTIVE POLYPODES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | L'OREAL (FR) | 1982-04-28 | — | — | EP | claimed |
| EP-0007097-A1 | Tensio-active polypodes, process for their preparation and compositions containing them | L'OREAL (FR) | 1980-01-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241041-A1 | LURBINECTEDIN IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | RXFP1, CIAPIN1, NMBR | CA1 1441/4885CA2 2036/4885MMP1 1022/4885 |
| US-20210061773-A1 | COMPOUND AND USE THEREOF IN MEDICINE | HDAC1, HDAC11, HDAC10 | CA1 3774/4885CA2 4470/4885MMP1 250/4885 |
| US-20170022210-A1 | PROCESS FOR IMPROVED OXYCODONE SYNTHESIS | OPRD1, OPRK1, HPD | CA1 2640/4885CA2 2664/4885MMP1 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.